← Leaderboards
Salomeh Keyhani
Northern California Institute/Res/Edu
$13,875,549
Attributed
$14,985,600
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,985,600 · 5
VA$0 · 4
By mechanism
R01$14,985,600 · 5
I01$0 · 3
IP1$0 · 1
Top collaborators
- Dawn Marie Bravata5 shared
- Teresa M. Damush5 shared
- Linda S Williams5 shared
- John Daniel Kelly4 shared
- Amy Lynn Byers3 shared
- Carolyn Gibson2 shared
Others in their field
Top investigators on “Veterans”
- David R. Weir · University Of Michigan At Ann Arbor$296,295,927
- Charles A Coltman · Southwest Oncology Group$122,561,996
- Jennifer A Pietenpol · Vanderbilt University$60,636,894
- Fred M Gordin · Social And Scientific Systems, Inc.$59,139,975
- Adrian Hernandez · Duke University$50,769,596
- Michael W. Konstan · Case Western Reserve University$48,783,827
Research focus
VeteransReportingMedicareCohortAreaHigh RiskSubgroupHospitalizationPharmaceutical PreparationsTextDesignPrevalenceRecording Of Previous EventsHealth AdministrationLinkBaseCharacteristicsResponseMarijuana UseRisk FactorsInnovationAdverse OutcomeMarijuana UserData Sources
Grant awards (38)
Long-term Neuropsychiatric Sequelae of SARS-CoV-2 Infection in Late Life$709,599
R01 · FY2025 · AG
VAccine failure: natural history and determinants of post-vaccination Covid-19$0
I01 · FY2025 · VA
Long-term Neuropsychiatric Sequelae of SARS-CoV-2 Infection in Late Life$744,308
R01 · FY2024 · AG
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy$0
I01 · FY2024 · VA · contact PI
VAccine failure: natural history and determinants of post-vaccination Covid-19$0
I01 · FY2024 · VA
Gaps in Identification, Referral and Treatment of Cannabis Use in VA Primary Care$0
I01 · FY2024 · VA · contact PI
Long-term Neuropsychiatric Sequelae of SARS-CoV-2 Infection in Late Life$766,195
R01 · FY2023 · AG
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury$562,671
R01 · FY2023 · AG · contact PI
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy$0
I01 · FY2023 · VA · contact PI
Gaps in Identification, Referral and Treatment of Cannabis Use in VA Primary Care$0
I01 · FY2023 · VA · contact PI
VAccine failure: natural history and determinants of post-vaccination Covid-19$0
I01 · FY2023 · VA
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury$578,070
R01 · FY2022 · AG · contact PI
VAccine failure: natural history and determinants of post-vaccination Covid-19$0
I01 · FY2022 · VA
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy$0
I01 · FY2022 · VA · contact PI
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury$597,805
R01 · FY2021 · AG · contact PI
PRIS-M: Precision Monitoring to Transform Care$0
IP1 · FY2021 · VA
PRIS-M: Precision Monitoring to Transform Care$0
IP1 · FY2021 · VA
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy$0
I01 · FY2021 · VA · contact PI
Impact of marijuana on adherence, risk factor control and cardiovascular events$691,027
R01 · FY2020 · HL · contact PI
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury$613,283
R01 · FY2020 · AG · contact PI
PRIS-M: Precision Monitoring to Transform Care$0
IP1 · FY2020 · VA
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy$0
I01 · FY2020 · VA · contact PI
PRIS-M: Precision Monitoring to Transform Care$0
IP1 · FY2020 · VA
Impact of marijuana on adherence, risk factor control and cardiovascular events$708,399
R01 · FY2019 · HL · contact PI
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury$674,449
R01 · FY2019 · AG · contact PI
PRIS-M: Precision Monitoring to Transform Care$0
IP1 · FY2019 · VA
Impact of marijuana on adherence, risk factor control and cardiovascular events$729,861
R01 · FY2018 · HL · contact PI
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy$638,263
R01 · FY2018 · HL · contact PI
Impact of marijuana on adherence, risk factor control and cardiovascular events$764,734
R01 · FY2017 · HL · contact PI
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy$709,749
R01 · FY2017 · HL · contact PI
An Evaluation of Novel Domains for Predicting 30-Day Readmission$585,633
R01 · FY2017 · HL · contact PI
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy$723,843
R01 · FY2016 · HL · contact PI
An Evaluation of Novel Domains for Predicting 30-Day Readmission$520,282
R01 · FY2016 · HL · contact PI
An Evaluation of Novel Domains for Predicting 30-Day Readmission$706,251
R01 · FY2015 · HL · contact PI
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy$733,294
R01 · FY2014 · HL · contact PI
An Evaluation of Novel Domains for Predicting 30-Day Readmission$718,710
R01 · FY2014 · HL · contact PI
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy$770,580
R01 · FY2013 · HL · contact PI
An Evaluation of Novel Domains for Predicting 30-Day Readmission$738,594
R01 · FY2013 · HL · contact PI